The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer

Ostheimer,Christian; Schweyer,Franziska; Reese,Thomas; Bache,Matthias; Vordermark,Dirk

doi:10.3892/ol.2016.5104

The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer

Authors:
- Christian Ostheimer
- Franziska Schweyer
- Thomas Reese
- Matthias Bache
- Dirk Vordermark
View Affiliations

Affiliations: Department of Radiation Oncology, Martin Luther University Halle‑Wittenberg, D‑06120 Halle (Saale), Germany
Published online on: September 8, 2016 https://doi.org/10.3892/ol.2016.5104
Pages: 3449-3456

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognostic quality of increased osteopontin (OPN) plasma levels has been demonstrated for the chemotherapy and surgery of lung cancer. There is also evidence in the literature that tumor volume impacts prognosis in definitive radiotherapy (RT) of (lung) cancer. We previously demonstrated that elevated plasma levels of OPN before, and increasing OPN plasma levels after RT significantly correlate with survival and outcome after curative‑intent RT of non‑small‑cell lung cancer (NSCLC). Tumor volume was also associated with prognosis. The present prospective clinical study investigated the prognostic interrelation of OPN plasma levels and tumor volume and their changes in the radical RT of NSCLC. We evaluated a subset of patients (n=27) with inoperable, non‑metastasized NSCLC of the previously published patient collective. Patients were treated with radical radiochemotherapy (2 Gy ad 66 Gy). OPN plasma concentrations were determined by ELISA before (t0), at the end (t1), and 4 weeks after RT (t2). GTV was delineated PET‑ and CT‑correlated before RT (GTV1) and after 40 Gy (GTV2). The course of OPN during and after RT and the change of GTV during RT was monitored over time and correlated with prognosis. Median GTV2 after 40 Gy (63 ml) was significantly lower than pre‑RT GTV1 (90 ml, P<0.0001). Median OPN before (t0), at the end of (t1) and four weeks after RT (t2) was 846, 777 and 624 ng/ml and not significantly different. GTV significantly declined by 39 ml during RT (P<0.0001) and OPN non‑significantly decreased by 56 ng/ml during (t0 to t1) and by 54 ng/ml after RT (t1 to t2). No correlations were determined between absolute OPN and GTV values or their relative changes during RT. In univariate analysis, only GTV2 significantly predicted overall survival (OS, P=0.03). In multivariate analysis, both OPN t1 (P<0.001) and GTV2 (P=0.001) remained significant predictors of OS. Relative OPN plasma level changes after (t1 to t2) and GTV changes during RT (GTV 1 to GTV 2) significantly predicted OS (P=0.02). The combination of absolute GTV values before RT (GTV1) and GTV changes during RT (GTV1 to 2) were significantly associated with OS in both uni‑ and multivariate analysis (P=0.03). The combination of absolute OPN plasma levels and their changes with GTV and its changes did not reach statistical significance. The lack of a significant correlation between OPN and GTV together with the finding that OPN and GTV remained independent predictors of survival outcome but were not associated with OS in combination supports the hypothesis that tumor volume (GTV) and OPN plasma levels (both their changes and absolute values) are not interrelated in terms of prognosis but do possess each parameter separately, a prognostic quality in the radical RT of NSCLC which justifies further prospective studies to validate these results.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
3	Vaupel P and Mayer A: Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
4	Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 77:18–24. 2005. View Article : Google Scholar : PubMed/NCBI
5	Le QT: Identifying and targeting hypoxia in head and neck cancer: A brief overview of current approaches. Int J Radiat Oncol Biol Phys. 69(Suppl 2): S56–S58. 2007. View Article : Google Scholar : PubMed/NCBI
6	Höckel M and Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol. 28(2): Suppl 8. S36–S41. 2001. View Article : Google Scholar
7	Zips D, Böke S, Kroeber T, Meinzer A, Brüchner K, Thames HD, Baumann M and Yaromina A: Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol. 187:306–310. 2011. View Article : Google Scholar : PubMed/NCBI
8	Bache M, Kappler M, Said HM, Staab A and Vordermark D: Detection and specific targeting of hypoxic regions within solid tumors: Current preclinical and clinical strategies. Curr Med Chem. 15:322–338. 2008. View Article : Google Scholar : PubMed/NCBI
9	Le QT and Courter D: Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 27:351–362. 2008. View Article : Google Scholar : PubMed/NCBI
10	Vordermark D and Brown JM: Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol. 179:801–811. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ostheimer C, Bache M, Güttler A, Kotzsch M and Vordermark D: A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol. 190:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ostheimer C, Bache M, Güttler A, Reese T and Vordermark D: Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 14:8582014. View Article : Google Scholar : PubMed/NCBI
13	Bradley JD, Leumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, Graham MV and Perez CA: Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 52:49–57. 2002. View Article : Google Scholar : PubMed/NCBI
14	Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH, Cho KH, Han JY, Lee YJ, Yun T, et al: The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol. 9:2832014. View Article : Google Scholar : PubMed/NCBI
15	Werner-Wasik M, Swann RS, Bradley J, Graham M, Emami B, Purdy J and Sause W: Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I–II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 70:385–390. 2008. View Article : Google Scholar : PubMed/NCBI
16	Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y and Nakaji S: Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume. Int J Radiat Oncol Biol Phys. 64:449–454. 2006. View Article : Google Scholar : PubMed/NCBI
17	Cox DR: Regression models and life tables. J Royal Stat Soc Series B (Methodological). 34:187–220. 1972.
18	Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, et al: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004. J Thorac Oncol. 4:1104–1110. 2009. View Article : Google Scholar : PubMed/NCBI
19	Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, et al: Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
20	Blasberg JD, Pass HI, Goparaju CM, Flores R, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
21	Alexander BM, Othus M, Caglar HB and Allen AM: Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 79:1381–1387. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kozak MM, Murphy JD, Schipper ML, Donington JS, Zhou L, Whyte RI, Shrager JB, Hoang CD, Bazan J, Maxim PG, et al: Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 6:920–926. 2011. View Article : Google Scholar : PubMed/NCBI
23	Stinchcombe TE, Morris DE, Moore DT, Bechtel JH, Halle JS, Mears A, Deschesne K, Rosenman JG and Socinski MA: Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer. 52:67–74. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG, Vinod SK, Krawitz HE, Joseph DJ, Wheeler GC and McClure BE: The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman radiation oncology group (TROG 99.05). Radiother Oncol. 106:305–311. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H and Ochiai A: A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: The prognostic importance of the area of residual tumor. J Thorac Oncol. 5:49–55. 2010. View Article : Google Scholar : PubMed/NCBI
26	Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, Thames HD, Krause M and Baumann M: GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol. 106:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wigren T: Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol. 44:9–15. 1997. View Article : Google Scholar : PubMed/NCBI
28	Contal C and O'Quigley J: An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 30:253–270. 1999. View Article : Google Scholar
29	Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 69:167–175. 2007. View Article : Google Scholar : PubMed/NCBI
30	Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, et al: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 12:1507–1514. 2006. View Article : Google Scholar : PubMed/NCBI
31	Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT and Le QT: Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys. 83:1521–1527. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, Wakelee HA, Graves EE and Loo BW: Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 13:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
33	Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC and Park CK: Effects of radiation therapy on the lung: Radiologic appearances and differential diagnosis. Radiographics. 24:985–998. 2004. View Article : Google Scholar : PubMed/NCBI
34	Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J and Baumann M: Exploratory prospective trial of hypoxia-specific PET-imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol. 105:21–28. 2012. View Article : Google Scholar : PubMed/NCBI
35	Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, et al: Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomark. 12:177–184. 2012.PubMed/NCBI